Diabetes Care
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Simha, V.
Right arrow Articles by Garg, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Simha, V.
Right arrow Articles by Garg, A.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Diabetes Care 26:30-35, 2003
© 2003 by the American Diabetes Association, Inc.

Clinical Care/Education/Nutrition
Original Article

Effect of Leptin Replacement on Intrahepatic and Intramyocellular Lipid Content in Patients With Generalized Lipodystrophy

Vinaya Simha, MD1,3, Lidia S. Szczepaniak, PHD2, Anthony J. Wagner, PHD4, Alex M. DePaoli, MD4 and Abhimanyu Garg, MD1,3

1 Division of Nutrition and Metabolic Diseases, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas
2 Division of Hypertension, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas
3 Center for Human Nutrition, Unviersity of Texas Southwestern Medical Center, Dallas, Texas
4 Amgen, Inc., Thousand Oaks, California

OBJECTIVE—To investigate whether leptin-induced improvements in glycemic control, hyperlipidemia, and insulin sensitivity in hypoleptinemic patients with generalized lipodystrophies are accompanied by reduction in intrahepatic and intramyocellular lipid (IMCL) accumulation.

RESEARCH DESIGN AND METHODS—We examined the effects 8–10 months of subcutaneous leptin replacement therapy on insulin sensitivity, IMCL, and intrahepatic lipid content in two patients with acquired generalized lipodystrophy and one patient with congenital generalized lipodystrophy. All patients had extreme lack of body fat, low plasma leptin levels, and elevated serum triglycerides, but only two had diabetes. Insulin sensitivity was measured by a high-dose (0.2 IU/kg) insulin tolerance test, as well as by hyperinsulinemic-euglycemic glucose clamp studies in two patients. IMCL and intrahepatic lipid content were measured by 1H magnetic resonance spectroscopy. All measurements were obtained before and during 2–10 months of leptin therapy.

RESULTS—Glycemic control and lipoprotein levels markedly improved with leptin therapy in the two diabetic patients, and a slight improvement in lipoprotein levels was seen in the nondiabetic patients. Insulin stimulated glucose uptake during 60–120 min of the euglycemic clamp studies, and the rate of glucose disappearance during the insulin tolerance test nearly doubled with leptin therapy. As compared with the baseline period, after 8–10 months of leptin therapy, the mean intrahepatic lipid content was reduced by ~80% and the IMCL content was reduced by ~42%.

CONCLUSIONS—Reduction in IMCL and intrahepatic lipid content may partly explain leptin-induced improvement in insulin sensitivity in patients with generalized lipodystrophy.

Abbreviations: AGL, acquired generalized lipodystrophy • CGL, congenital generalized lipodystrophy • IMCL, intramyocellular lipid • SC, subcutaneous


Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 CirculationHome page
J. M. McGavock, I. Lingvay, I. Zib, T. Tillery, N. Salas, R. Unger, B. D. Levine, P. Raskin, R. G. Victor, and L. S. Szczepaniak
Cardiac Steatosis in Diabetes Mellitus: A 1H-Magnetic Resonance Spectroscopy Study
Circulation, September 4, 2007; 116(10): 1170 - 1175.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
J. J. Dube, B. A. Bhatt, N. Dedousis, A. Bonen, and R. M. O'Doherty
Leptin, skeletal muscle lipids, and lipid-induced insulin resistance
Am J Physiol Regulatory Integrative Comp Physiol, August 1, 2007; 293(2): R642 - R650.
[Abstract] [Full Text] [PDF]

Home page
 J. Appl. Physiol.Home page
W. Huang, N. Dedousis, and R. M. O'Doherty
Hepatic steatosis and plasma dyslipidemia induced by a high-sucrose diet are corrected by an acute leptin infusion
J Appl Physiol, June 1, 2007; 102(6): 2260 - 2265.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
W. Huang, N. Dedousis, A. Bandi, G. D. Lopaschuk, and R. M. O'Doherty
Liver Triglyceride Secretion and Lipid Oxidative Metabolism Are Rapidly Altered by Leptin in Vivo
Endocrinology, March 1, 2006; 147(3): 1480 - 1487.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
L. S. Szczepaniak, P. Nurenberg, D. Leonard, J. D. Browning, J. S. Reingold, S. Grundy, H. H. Hobbs, and R. L. Dobbins
Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population
Am J Physiol Endocrinol Metab, February 1, 2005; 288(2): E462 - E468.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
E L Thomas, G Hamilton, N Patel, R O'Dwyer, C J Dore, R D Goldin, J D Bell, and S D Taylor-Robinson
Hepatic triglyceride content and its relation to body adiposity: a magnetic resonance imaging and proton magnetic resonance spectroscopy study
Gut, January 1, 2005; 54(1): 122 - 127.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
M. Korach-Andre, J. Gao, J. S. Gounarides, R. Deacon, A. Islam, and D. Laurent
Relationship between visceral adiposity and intramyocellular lipid content in two rat models of insulin resistance
Am J Physiol Endocrinol Metab, January 1, 2005; 288(1): E106 - E116.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
E. D. Javor, S. A. Moran, J. R. Young, E. K. Cochran, A. M. DePaoli, E. A. Oral, M. A. Turman, P. R. Blackett, D. B. Savage, S. O'Rahilly, et al.
Proteinuric Nephropathy in Acquired and Congenital Generalized Lipodystrophy: Baseline Characteristics and Course during Recombinant Leptin Therapy
J. Clin. Endocrinol. Metab., July 1, 2004; 89(7): 3199 - 3207.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
W. Huang, N. Dedousis, B. A. Bhatt, and R. M. O'Doherty
Impaired Activation of Phosphatidylinositol 3-Kinase by Leptin Is a Novel Mechanism of Hepatic Leptin Resistance in Diet-induced Obesity
J. Biol. Chem., May 21, 2004; 279(21): 21695 - 21700.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
A. Garg
Acquired and Inherited Lipodystrophies
N. Engl. J. Med., March 18, 2004; 350(12): 1220 - 1234.
[Full Text] [PDF]

Home page
 DiabetesHome page
P. J. Havel
Update on Adipocyte Hormones: Regulation of Energy Balance and Carbohydrate/Lipid Metabolism
Diabetes, February 1, 2004; 53(90001): S143 - 151.
[Abstract] [Full Text]

Home page
 Am. J. Clin. Nutr.Home page
L. K Heilbronn and E. Ravussin
Calorie restriction and aging: review of the literature and implications for studies in humans
Am. J. Clinical Nutrition, September 1, 2003; 78(3): 361 - 369.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2003 by the American Diabetes Association.